NRG Oncology Semiannual Meeting

SUMMER 2025 SYMPOSIUM

Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors

Thursday, July 24, 2025
8 am - 12:15 pm - Washington, DC



Program Booklet

SPONSORED BY: GOG FOUNDATION® *Transforming the standard of care* NRG ONCOLOGY *Advancing Research. Improving Lives.™*

FACULTY DISCLOSURE INFORMATION

Summer 2025 Symposium
"Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors"
Thursday, July 24, 2025
Washington, DC

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company *(**formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM ***An **"ineligible company" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

NAME	Individual's Role(s) in Activity	Nothing To Disclose	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
Planning Disclosures				
Moore, Kathleen, MD	**Planner/ Moderator**		Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation; GOG Partners; NRG Ovarian Committee Chair; Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmacetuicals; GSK/Tesaro; Duality Biologics; Artios; Amgen; Schrodinger; Daiichi Sankyo/Lilly;	Honoraria (Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation Leadership (GOG Partners; NRG Ovarian Committee Chair) Consulting or Advisory Role (Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmacetuicals; GSK/Tesaro; Duality Biologics; Schrodinger) Research Funding (Merck; Regeneron; Verastem; AstraZeneca; Immunogen; Artios; Amgen; Daiichi Sankyo/Lilly; Immunocore) Patents, Royalties, Other Intellectual Property (Up to Date)

			Regeneron; Up to Date; BioNTech SE	Travel, Accommodations, Expenses (BioNTech SE)
Tarantino, Paolo, MD	**Planner/ Moderator**		AstraZeneca, Daiichi Sankyo, Novartis, Menarini/Stemline, Gilead, Eli Lilly	Consultant (AstraZeneca; Daiichi Sankyo; Gilead; Eli Lilly) Advisor (AstraZeneca; Daiichi Sankyo; Novartis; Menarini/Stemline) Speaker (AstraZeneca; Daiichi Sankyo)
Speaker Disclosures				
Cecchini, Michael, MD	**Speaker**		AbbVie; Beigene; Incendia Therapeutics; Taiho; Arcus; Ipsen; BeOne Oncology; BioAlta; Medilink; Genentech, Astellas; Parbilis Medicines; 858 Therapeutics; Janssen; Eli Lilly	Honoraria/Advisory Role (AbbVie; Beigene; Incendia Therapeutics; Taiho; Arcus) Travel (Ipsen) Research Funding paid to Institution (AbbVie; Arcus; BeOne Oncology; BioAlta; Medilink; Genentech, Astellas; Parabalis Medicines; Ipsen; 858 Therapeutics; Janssen; Eli Lilly)
Ellisen, Leif W., MD, PhD	**Speaker**		Gilead; Astra-Zeneca; Atavistik; Kisoji	Consultant
Gupta, Shilpa, MD	**Speaker**		Bristol Meyers Squibb; Merck; J&J; AstraZeneca; BionTech; Nektar Therapeutics; UpToDate; BMS; Pfizer; Roche; Tyra Biosciences; Flare Therapeutics; Convergent Therapeutics; Novartis	Advisory Role (Bristol Meyers Squibb; Merck; J&J; AstraZeneca) Honoraria (Merck) Speaker's Bureau (Bristol Meyers Squibb) Stock (BionTech; Nektar Therapeutics) Intellectual Property, Patents, Proprietary Interests (UpToDate) Research Funding Site PI (Merck; BMS; Pfizer; Roche; Tyra Biosciences; Flare Therapeutics; Convergent Therapeutics; Novartis)
Krop, Ian, MD	**Moderator/ Speaker**		EMD Serono; AstraZeneca; Daiichi Sankyo; Puretech; Johns Hopkins	Honoraria (EMD Serono; AstraZeneca; Daiichi Sankyo) Employment of Immediate Family Member-has Ended (Puretech) Intellectual Property, Patents, Proprietary Interests (Johns Hopkins)
Liu, Joyce, MD	**Moderator**		AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Dicephera Pharmaceuticals; Bristol-Meyers Squibb	Advisory Board ad hoc. (AstraZeneca; Daiichi Sankyo; Eisai; Genentech) Scientific Ad Board (Dicephera Pharmaceuticals) Consulting (Bristol-Meyers Squibb)
LoRusso, Patricia, DO, PhD	**Speaker**		Takeda; Agenus; Pfizer; Glaxo-Smith Kline; Kyowa Kirin Pharmaceutical Development; Kineta; I-Mab; Mekanistic; Acuate Therapeutics; Atreca Development; Schrodinger; Prelude; Wells Therapeutics; Kivu; Compass Tx; Zai Lab; Abdera; AstraZeneca; EMD Serono; Quanta Therapeutics; Cullinan; Boehringer Ingelheim; SOTIO; (Amgen CodeBreak 202; DrenBio; National Cancer Institute/NIH/DDHS; AstraZeneca Pharmaceutical LP; Merck; NIH/NCI; University of Michigan; Gateway for Cancer Research	Advisory Board (Takeda; Agenus; Pfizer; Glaxo-Smith Kline; Kyowa Kirin Pharmaceutical Development; Kineta; I-Mab; Mekanistic; Actuate Therapeutics; Atreca Development; Schrodinger; Prelude; Wells Therapeutics; Kivu; Compass Tx; Zai Lab; Abdera; AstraZeneca; EMD Serono) Clinical Advisory Board (Quanta Therapeutics) Scientific Advisory Board (Cullinan) STING Agonist Global Advisory Board (Boehringer Ingelheim) Consultant (SOTIO; I-Mab) Data Monitoring Committee (Amgen CodeBreak 202) Data Safety Monitoring Board (DrenBio) Research Funding (National Cancer Institute/NIH/DDHS; AstraZeneca Pharmaceutical LP; Merck; Genentech Inc.;

GOG FOUNDATION® Transforming the standard of care

FACULTY DISCLOSURE INFORMATION

				NIH/NCI; University of Michigan; Gateway for Cancer Research/ASCO)
Maues, Julia	**Speaker**	**X**		
Moore, Kathleen, MD	**Moderator/ Speaker**		Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation; GOG Partners; NRG Ovarian Committee Chair; Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmacetuicals; GSK/Tesaro; Duality Biologics; Artios; Amgen; Schrodinger; Daiichi Sankyo/Lilly; Regeneron; Up to Date; BioNTech SE	Honoraria (Research To Practice; Company: Prime Oncology; Great Debates and Updates; Corcept; Abbvie; Nykode Therapeutics; third arc; Astellas Medivation Leadership (GOG Partners; NRG Ovarian Committee Chair) Consulting or Advisory Role (Genentech/Roche; Immunogen; AstraZeneca; Merck; Eisai; Verastem/Pharmacyclics; AADi; Caris Life Sciences; Iovance Biotherapeutics; Janssen Oncology; Regeneron; zentalis; Daiichi Sankyo Europe GmbH; Novacure; BioNTech SE; immunocore; Sanofi/Aventis; seagen; Takeda Science Foundation; zymeworks; profound bio; Mersana; Blueprint pharmacetuicals; GSK/Tesaro; Duality Biologics; Schrodinger) Research Funding (Merck; Regeneron; Verastem; AstraZeneca; Immunogen; Artios; Amgen; Daiichi Sankyo/Lilly; Immunocore) Patents, Royalties, Other Intellectual Property (Up to Date) Travel, Accommodations, Expenses (BioNTech SE)
Naqash, Abdul Rafeh, MD	**Speaker**		Foundation Med; JCO Precision Oncology; Jazz Pharma; Loxo@Lilly; Surface Oncology; ADC Therapeutics; IGM Biosciences; EMD Serono; Aravive; Nikang Therapeutics; Inspirna; Exelexis; Revolution Medicine; Jacobio; Pionyr; Jazz Pharmaceuticals; NGM Biopharmaceuticals; Immunocore, Phanes Therapeutics; Kymera Therapeutics	Honoraria (Foundation Med) Consultant (JCO Precision Oncology) Travel (Jazz Pharma) Research Funding to Institution (Loxo@Lilly; Surface Oncology; ADC Therapeutics; IGM Biosciences; EMD Serono; Aravive; Nikang Therapeutics; Inspirna; Exelexis; Revolution Medicine; Jacobio; Pionyr; Jazz Pharmaceuticals; NGM Biopharmaceuticals; Immunocore, Phanes Therapeutics; Kymera Therapeutics)
Price, Lauren, PharmD	**Speaker**	**X**		
Ricciuti, Biagio, MD	**Speaker**		AstraZeneca; Regeneron; AbbVie; Bayer; BMS; Caris Life; SITC	Consultant (AstraZeneca; Regeneron; AbbVie; Bayer; BMS; Caris Life) Speaker Fee (AstraZeneca) Honorarium (SITC)
Tarantino, Paolo, MD	**Moderator/ Speaker**		AstraZeneca, Daiichi Sankyo, Novartis, Menarini/Stemline, Gilead, Eli Lilly	Consultant (AstraZeneca; Daiichi Sankyo; Gilead; Eli Lilly) Advisor (AstraZeneca; Daiichi Sankyo; Novartis; Menarini/Stemline) Speaker (AstraZeneca; Daiichi Sankyo)
Holley Engbert	**Staff**	**X**		
Heather Rush	**Staff**	**X**		
Kara Shumaker	**Reviewer/Staff**	**X**		
Michelle N Small, MPH	**Reviewer/Staff**	**X**		
Angeles Alvarez Secord, MD	**Reviewer/Edu-Chair**		AZ, Abbvie; Aravive; Clovis, Eisai, Ellipses Pharma, Roche/Genentec ; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck;	Research funds to institution (AZ, Abbvie; Aravive; Clovis; Eisai; Ellipses Pharma; Roche/Genentec; GSK; I-MAB Biopharma; Immunogen; Karyopharm; Merck; Mersana;

FACULTY DISCLOSURE INFORMATION

			Mersana; Seagen; VBL Therapeutics; Zentalis; Gilead; Oncoquest/Canaria BIo	Seagen; VBL Therapeutics; Zentalis; Oncoquest/Canaria BIo) Adboard (Abbvie) Uncomp AdBoard (Gilead; Oncoquest/Canaria Bio; Aravive; VBL) SteeringCommitte (Aravive; VBL; Oncoquest/Canaria Bio)
Linda Duska, MD	**Reviewer/Edu-Co-Chair**		Regeneron; Aadi Bioscience; Daiichi Sankyo; Agenus; NX Development Corp	Advisory Board (Regeneron; Aadi Bioscience; Daiichi Sankyo) Data Safety Monitoring -Money to institution (Agenus) NX Development Corp
Stephanie Blank, MD	**Reviewer**		AstraZeneca; Merck; Zentalis; Acrivon; Seattle Genetics; GSK	Research Funding to Institution
David Mutch, MD	**Reviewer**	**X**		
Susan Zweizig, MD	**Reviewer**	**X**		

CONTINUING MEDICAL EDUCATION (CME)

Accreditation Statement

The GOG Foundation, Inc. is accredited by the ACCME to provide Continuing Education for physicians.

AMA PRA Category 1 Credits™

The GOG Foundation, Inc. designates this live activity for a maximum of **4 AMA PRA Category 1 Credits™**.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The GOG Foundation Inc. Continuing Education (CME) Program Mission Statement

The purpose of The GOG Foundation, Inc. CME program is to provide and promote an infrastructure dedicated to enhancing the knowledge base of meeting participants and guests centered on the development, execution, analysis and application of GOG-supported clinical trials. To that end, the CME Program engages in these discussions member researchers and invited clinicians committed to reducing the risk and improving outcomes for women at risk for or afflicted with a gynecologic malignancy.

Disclosure Declaration

In compliance with ACCME regulations, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation. Please see the complete disclosure list included with this program.

Off-Label Statement

Some of the presentations and discussions in this session may include the off-label use of products/ devices.

How do I collect CME Certificates?

Evaluation Link and QR code
https://s.pointerpro.com/sumsym7-25

- **Scan QR code or click link** above to complete evaluation.
- **Click submit** and your certificate will automatically be emailed to you.

CME Evaluations must be submitted by: August 11, 2025.

If you have issues accessing your certificate or questions about CMEs, please contact: cmeinfo@gog.org.

Slide Presentations

A PDF version of all final slide presentations are available in the Symposium Session content on the Attendee Hub and the Meeting App

For questions or comments about this CME activity, please contact: Michelle N. Small, MHA
Dir, Education Programs/CME Compliance
at msmall@gog.org

Symposium - Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors

Thursday, July 24, 2025 - 8 - 12:15 pm EST

Program Chair - Kathleen Moore, MD
Co-Chair - Paolo Tarantino, MD

Program Description

The use of antibody-drug conjugate (ADC) therapy has ushered in a new era in oncology, significantly transforming the management of a range of solid tumor malignancies. This session offers a valuable opportunity to explore the expanding role of ADCs in the treatment of ovarian, cervical, endometrial, breast, lung, genitourinary and gastrointestinal cancers, highlighting their impact on clinical practice and patient outcomes. The latest practice-changing clinical trial results will be provided and reviewed in context with challenging clinical practice scenarios in cancer patients treated with ADC. Expert led discussions will provide evidence-based perspectives regarding important clinically relevant topics in drug selection, biomarkers, sequencing, and toxicity management. We will also review the future landscape of care and current as well as upcoming clinical trials. This timely and clinically relevant session aims to equip attendees with actionable knowledge that can be immediately applied in oncology practice.

Interactive case vignettes will offer practical guidance on patient selection, therapeutic strategies, and the management of adverse effects associated with ADCs. Additionally, ongoing and planned pivotal clinical trials will be discussed and the future of clinical trial design in the era of current ADC and novel future therapies will be explored.

Learning Objectives

Following this activity, participants will be better able to:

- **Explain** the development and mechanism of action of antibody-drug conjugates (ADCs) and identify mechanisms of resistance.
- **Discuss** the clinical application of ADCs in the treatment of gynecologic, breast, lung, genitourinary (GU), and gastrointestinal (GI) malignancies.
- **Recognize** and **Manage** adverse events associated with ADC therapy.

Target Audience

This symposium is intended for a broad oncology-focused audience, including members and non-members. Participants may include physicians, research staff, early-career investigators, clinical research associates, basic scientists, medical physicists, clinical trial nurses, patient advocates, and other healthcare professionals involved in cancer treatment and research.

See presentation agenda on next page

Sponsored by the NRG Oncology and the GOG Foundation

Summer 2025 Symposium

Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors

Thursday, July 24, 2025 – NRG Oncology Semiannual Meeting - Washington, DC

Presentation Agenda

Program Chair: Kathleen Moore, MD / Co-Chair Paolo Tarantino, MD

Presentation Agenda Time	Topic/Title	Speaker/Moderator
6:30 am	**Full Breakfast Buffet**	
8:00 am	**Welcome/Opening Remarks**	**Kathleen Moore, MD**
8:05-9:35am	**Session 1 *"Selection and ADCs in Gynecologic, Breast, Lung, GU and GI Cancers"***	**Moderators: Ian Krop, MD**
8:05 – 8:20	**How do ADCS actually work? Magic Bullets or Just Fancy Chemotherapy?**	**Patricia LoRusso, DO, PhD**
8:20 – 8:35	**ADCs in Breast Cancer**	**Ian Krop, MD**
8:35 – 8:50	**Expanding ADCs in Lung Cancer**	**Biagio Ricciuti, MD**
8:50 – 9:05	**Evolution of ADCs in GI Oncology**	**Michael Cecchini, MD**
9:05 – 9:20	**Evolution of ADCs in GU Oncology**	**Shilpa Gupta, MD**
9:20 - 9:35 am	**Panel Discussion with Q/A**	**ALL**
9:35 – 10:50 am	**Session 2: *"Selection, Sequencing and Mechanism of Resistance- Patient Centric Development of ADCs"***	**Moderator: Paolo Tarantino, MD**
9:35 – 9:55	**ADC Landscape in Gynecologic Cancers**	**Ramez Eskander, MD**
9:55 - 10:15	**Mechanisms of Resistance and Impact on ADC Sequencing**	**Paolo Tarantino, MD**
10:15 – 10:35	**ADC Toxicity: A Reality Check from Patients Living It**	**Julia Maues**
10:35 – 10:50	**Panel Discussion with Q/A**	**ALL**
10:50 – 11:00	**Coffee Break**	
11:00 – 12:05 pm	**Session 3: *"Future Developments, Optimization, and Safety"***	**Moderator: Joyce Liu, MD –**
11:00 – 11:20	**New Frontiers of ADCs: ISACs, DACs, bispecific ADCs and beyond**	**Abdul Rafel Raqash, MD**
11:20 – 11:40	**Boosting the Activity of ADCs with Combinations**	**Leif W. Ellisen, MD, PHD**
11:40 - 12:00	**Regimen Optimization and Regulatory Considerations in ADC Development**	**Lauren Price, PharmD**
12:00 – 12:10 pm	**Panel Discussion with Q/A**	**ALL**
12:10 pm	**Closing Remarks**	**Kathleen Moore, MD and Paolo Tarantino, MD**

Off-Label Statement:
Some of the presentations and discussions in this session may include the off-label use of products/devices.

PROGRAM CHAIR

Kathleen Moore, MD, MS
Deputy Director
Co-Director Cancer Therapeutics Program
Stephenson Cancer Center at OU Health
Professor, Gynecologic Oncology
University of Oklahoma, HSC

Kathleen Moore, MD, is Deputy Director of the Stephenson Cancer Center and professor in the Department of Obstetrics and Gynecology at Stephenson Cancer Center (SCC), University of Oklahoma. She earned her MD from the University of Washington, followed by a residency in obstetrics-gynecology at Magee-Womens Hospital in Pittsburgh, and a fellowship in gynecologic oncology at the University of Oklahoma Health Sciences Center.

Dr Moore is principal investigator for SCC's National Cancer Institute U10 National Clinical Trials Network Lead Academic Participating Site award, the SCC UM1 ETCTN award, and MPI on the SCC Cancer Screening Research Network UG1. In these roles, she oversees clinical research development and operations. She works to establish collaborations between scientists and clinicians to develop translational and biomarker-driven studies and clinical trials, and develop the infrastructure for clinical trials and translational research.

She has leveraged success in some of these trials into more directed studies in specific gynecologic populations in an attempt to move promising agents into larger, more accessible trials through the cooperative-group mechanism. She has overseen phase I trials and safety lead-ins for her site since 2009.

Dr Moore serves as chair of NRG's Ovarian Cancer Committee, and as a member of the Developmental Therapeutics Committee and on the GOG Foundation BOD. She is a member of the American Society of Clinical Oncology and was elected to the BOD. Her research has appeared in several respected peer-reviewed publications, including the Journal of Clinical Oncology, New England Journal of Medicine, Cancer, and Clinical Cancer Research.

PROGRAM CO-CHAIR

Paolo Tarantino, MD
Breast Medical Oncologist/Clinical Researcher
Dana-Farber Cancer Institute

Paolo Tarantino, MD is a breast medical oncologist and clinical researcher. He's obtained his medical degree at the University Federico II of Naples (Italy) and completed his medical oncology training at the European Institute of Oncology in Milan (Italy). In 2021 he joined the Breast Oncology Center of the Dana-Farber Cancer Institute and Harvard Medical School (Boston, MA), where he's currently pursuing a clinical fellowship.

His research focuses on the development of novel drugs for treating breast cancer, with particular focus on antibody-drug conjugates. Her has published over 100 scientific articles on the topic, and he is currently conducting multiple clinical trials and preclinical investigations to increase the precision of ADC treatment for patients with breast cancer.

MODERATORS / SPEAKERS

Michael Cecchini, MD
Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers; Medical Oncology Section Lead for National Accreditation Program for Rectal Cancer, Internal Medicine; Co-Director, GI Clinical Research Team; Phase 1 Investigator
Yale Cancer Center

Bio coming soon

Leif W. Ellisen, M.D., Ph.D.
Nelson Family and Jerry Younger Endowed Chair
Program Director, Breast Medical Oncology, MGH Cancer Center
Co-Leader, DF/HCC Breast Cancer Program
Investigator, Ludwig Center at Harvard
Professor of Medicine, Harvard Medical School

Dr. Leif W. Ellisen is the Breast Cancer Program Director and the Nelson/Younger Endowed Chair in breast cancer research at the Massachusetts General Hospital (MGH) Cancer Center. He is also co-leader of the Breast Cancer program at the Dana-Farber/Harvard Cancer Center, Professor of Medicine at Harvard Medical School, and an Investigator of the Ludwig Center at Harvard. Dr. Ellisen received his AB degree from Harvard University, MD and PhD degrees from Stanford University, and completed post-doctoral clinical and research training at Brigham and Women's Hospital, Dana-Farber Cancer Institute, and MGH. In addition to his clinical practice, Dr. Ellisen oversees clinical research within the MGH Breast Cancer Program involving clinical trials for all stages and subtypes of breast cancer. Dr. Ellisen also directs a basic and translational research program in breast cancer, incorporating studies of tumor evolution, metabolism and drug resistance. Dr. Ellisen's most recent work has focused on defining mechanisms of de novo and acquired resistance to antibody drug conjugates as a means to develop novel therapeutic combinations incorporating these agents.

MODERATORS / SPEAKERS

Ramez N. Eskander, MD
Associate Professor of Gynecologic Oncology
Fellowship Director
Co-Director, UC San Diego International Patient Program Center for Personalized Cancer Therapy
Center for Precision Immunotherapy
UC San Diego Moores, NCI Designated, Comprehensive Cancer Center

Ramez Eskander, MD, is a board-certified gynecologic oncologist who specializes in the comprehensive management of female reproductive system cancers, including ovarian, uterine, cervical, vulvar and vaginal cancer. His expertise includes diagnostic and therapeutic procedures, state-of-the-science treatment strategies, as well as minimally invasive (robotic) surgery, hyperthermic intraperitoneal chemotherapy (HIPEC) and novel drugs. Dr. Eskander is also experienced in developing and leading national and international clinical trials, with an aim to provide individuals with access to innovative medicines during their treatment.
As an associate professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences, Dr. Eskander instructs medical students, residents, and fellows at UC San Diego School of Medicine. He is also the gynecologic oncology fellowship director. Dr. Eskander's research focuses on immunotherapy, targeted therapies, new combinatorial treatment approaches and a better understanding of the implications of molecular tumor testing on treatment outcomes.

Dr. Eskander has co-authored over 100 peer-reviewed articles, several book chapters and is the co-editor of Gynecologic Oncology: A Pocketbook. He speaks frequently at annual medical conferences and his work has been published in journals such as Journal of Clinical Oncology, Obstetrics and Gynecology, Gynecologic Oncology and Clinical Cancer Research, among others. In 2015, he was awarded the Society of Gynecologic Oncology's John L. Lewis Jr. Presidential Award for most influential scientific paper.

Prior to joining UC San Diego Health, Dr. Eskander was an assistant professor in the Department of Obstetrics and Gynecology at UC Irvine School of Medicine, also caring for patients with gynecologic cancers.
Dr. Eskander completed a fellowship in gynecologic oncology at UC Irvine School of Medicine and a residency in obstetrics and gynecology at UC San Diego School of Medicine, where he also earned his medical degree. He is board-certified in obstetrics and gynecology and gynecologic oncology.

Dr. Eskander is a member of many professional organizations, and is also a member of GOG-Partners, the leading national organization in the design and conduct of gynecologic cancer clinical trials.
Outside of work, Dr. Eskander enjoys spending time with his wife and two daughters. He is actively involved in his church community, where he teaches 7th and 8th grade Sunday school. Dr. Eskander also enjoys traveling and outdoor activities, including running and cycling. He speaks Arabic and Spanish fluently.

MODERATORS / SPEAKERS

Shilpa Gupta, MD
Clinical Trials Office
Chief Clinical Research Officer
Yale Cancer Center; Associate Director,
Clinical Sciences, Yale Cancer Center

Shilpa Gupta, MD is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.

Dr. Gupta obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at the University of Connecticut Health Center. She completed Hematology-Oncology fellowship at Georgetown University and Thomas Jefferson University followed by a Genitourinary Oncology Translational Research fellowship at Thomas Jefferson University. Dr. Gupta was a faculty at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in the Departments of Genitourinary Oncology and Experimental Therapeutics from 2011 until 2015. From 2015 until 2019, she was Associate Professor and Lead for the Solid Tumor Phase 1 Program at Masonic Cancer Center, University of Minnesota. Dr. Gupta serves on the ASCO Annual Scientific Committee for Genitourinary Cancers and SITC Anti-PD-1/PD-L1 Resistance Task Force. She is also on the panel of the SITC Cancer Immunotherapy Guidelines and the International Bladder Cancer Groups core committee and Society of International Urology Innovators

Dr. Gupta's research interests are novel drug development and understanding biomarkers of response and resistance to therapies in bladder cancer. Dr. Gupta has led several Investigator Initiated Trials in Genitourinary Cancers and has leadership roles in NCI trials and is Chair of an Alliance led phase 3 trial in Bladder Cancer, Co-Chair of SWOG S1206 trial in Prostate Cancer and SWOG champion of the Alliance A031701 trial in Bladder Cancer. She is Principal Investigator of 2020 Department of Defense Idea Award to study the biomarkers of response and resistance to immunotherapy in bladder cancer and Co-Principal Investigator of Department of Defense Team Translational Science Award to study immunotherapy combination strategies to overcome resistance in bladder cancer. Dr. Gupta is the Co-Chair of the Hoosier Cancer Research Network (HCRN) Genitourinary Working Group and Co-Chair of the Case Comprehensive Cancer Center PRMC committee.

Her research work has been published in peer-reviewed journals including the Journal of Clinical oncology, Lancet Oncology, Clinical Cancer Research, European oncology, among others. She is the author for the AUA core curriculum for penile cancer and serves on the NCCN Guidelines Panel for Prostate Cancer.

Dr. Gupta is active in several professional organizations including the American Society of Clinical Oncology (ASCO), American Urologic Association (AUA), American Association of Cancer Research (AACR), Society of Urologic Oncology (SUO), Society of Immunotherapy for cancer (SITC), Bladder Cancer Advocacy Network (BCAN), Prostate Cancer Foundation (PCF) and the European society of Medical Oncology (ESMO).

MODERATORS / SPEAKERS

Ian Krop, MD
Director,
Clinical Trials Office
Chief Clinical Research Officer
Yale Cancer Center; Associate Director,
Clinical Sciences, Yale Cancer Center

Bio coming soon

Joyce Liu, MD
Associate Chief, Division of Gynecologic Oncology
Director of Clinical Research, Division of Gynecologic Oncology
Associate Clinical Research Officer,
Clinical Research Program
Associate Professor of Medicine, Harvard Medical School

Joyce Liu, MD, MPH is an Assistant Professor of Medicine at Dana Farber Cancer Institute and Harvard Medical School. She is a medical oncologist specializing in the treatment of women with gynecologic malignancies. She is the Associate Chief and the Director of Clinical Research for the Division of Gynecologic Oncology at Dana-Farber Cancer Institute as well as the Associate Clinical Research Officer for Dana-Farber Cancer Institute.

Dr. Liu received her medical degree from Harvard Medical School and subsequently completed her residency in Internal Medicine at Brigham and Women's Hospital and her fellowship in Medical Oncology at Dana-Farber Cancer Institute. She also has a Master of Public Health from the Harvard School of Public Health. Dr. Liu's research focuses on identifying and validating novel therapies and therapeutic combinations for gynecologic cancers. She is an active member of NRG, where she is a member of the Developmental Therapeutics committee and is the vice chair of the Ovarian Subcommittee. She has received grant support from the National Cancer Institute, the American Society of Clinical Oncology (ASCO), and the Ovarian Cancer Research Fund Alliance. She has served on ASCO guideline committees and is a member of the NCCN Ovarian Cancel Panel.

MODERATORS / SPEAKERS

Patricia LoRusso, DO, PhD
Director: Early Phase Clinical Trials Program
Yale Cancer Center, Yale University

Patricia LoRusso, DO, PhD has been a practicing academic medical oncologist performing clinical/translational research in early phase clinical trials for 35 years, spending the first 25 years at Wayne State University/Karmanos Cancer Institute in Detroit, MI and transitioning to Yale University/Yale Cancer Center in 2014. She has had continuous NIH/NCI peer review funding for 33 years, having held a U-grant for early phase clinical trials through the NCI Cancer Therapy Evaluation Program (CTEP) for 28 years. She has also collaborated on numerous other grants and have been an investigator in R01, P01 and P30 funding mechanisms. Understanding the need for team science, she has participated in P50 mechanisms and has been awarded team science grants through such organizations as Stand Up to Cancer (Co-Leader: Melanoma Dream Team), the Department of Defense (DOD) and the Komen Foundation (Co-leader, KG111063:Targeting Stem Cells in Triple-Negative Breast Cancer (TNBC) in Different Racial Populations).

Dr. LoRusso has also been involved in many service disciplines at the NCI and elsewhere. She has reviewed grants for many study sections and has either been an ad hoc (e.g. CCSG, NeXT study sections) or permanent study section member (e.g. Program Project Subcommittee D and Clinical Oncology study sections). She has served on the Investigational Drug Steering Committee (IDSC) since inception (2005-present) and served as its chair from 2011-2013 and 2022-2024. She was a member of the steering committee that convened after the Blue- Ribbon Panel to execute on their recommendations. She served a 9-year term (2015-2024) on the Board of Scientific Council (BSC), reviewing the intramural programs for quality, content, productivity and funding.
In addition to serving in NCI positions, Dr. LoRusso has served in leadership positions of several other organizations. She has served on the Board of Directors and numerous scientific and education committees of the American Association for Cancer Research (AACR) as well as the AACR President from 2024-2025. She is currently the Immediate Past President of AACR. She has served on education and scientific committees of the American Society of Clinical Oncology (ASCO), and the steering committee for the Food and Drug Administration (FDA) Accelerating Anticancer Agent Development and Validation Workshop, as examples. Internationally, she has taught several clinical trials educational workshops, educating many physicians and scientists across the globe. She understands how critically important it is to train the next generation of early career investigators to be knowledgeable and proficient in clinical and translational research by providing them leadership opportunities and mentoring. She has worked closely with Cancer Research United Kingdom (CRUK), a UK Welcome Trust which is the second largest funding agency for cancer research. She is currently the chair of their New Agents Committee (NAC), reviewing international proposals relative to drug development of novel agents.

Working closely over the past 3 decades with patients suffering from advanced malignancies, Dr. LoRusso has become an advocate, not only for junior through senior faculty cancer researchers and clinicians, but more importantly for the patients and their caregivers. Having experienced at a young age the death of her own parents from cancer, she understands the urgent need for new cancer discoveries and the potential for longevity and quality of life. She is committed to training the next generation of physician scientists and clinical researchers, to advance novel therapies to increase outreach of novel therapeutics to cancer patients globally.

MODERATORS / SPEAKERS

Julia Maues

Bio coming soon

Abdul Rafeh Naqash, MD
Asst. Professor of Medicine
Medical Oncology/ TSET Phase 1 Program
Director of Immuno-Oncology
Stephenson Cancer Center
The University of Oklahoma

Abdul Rafeh Naqash, MD received his medical degree at the Government Medical College Srinagar, Kashmir. He completed Internal Medicine residency training at the University of Buffalo/Catholic Health. Subsequently, Dr. Naqash completed his sub-specialty clinical training in Hematology/Oncology at East Carolina University, Greenville, NC and a early phase clinical trial fellowship at the National Cancer Inst, Bethesda in the developmental therapeutics clinic. As part of the TSET phase 1 program at Stephenson Cancer Center, Dr. Naqash is focusing his interest in drug development and incorporating a genomically driven approach to early phase clinical trials. He is also interested in Lung Cancer, immunotherapy biomarkers , understanding resistance patters to Immunotherapy and immune toxicities. Dr. Naqash has led and collaborated extensively with national and international leaders in the field of immunotherapy. Some of this work has been published in high impact journals such as Journal of Clinical Oncology, JAMA Oncology, Journal of Immunotherapy of Cancer, Clinical Cancer Research among others. Dr. Naqash has been the recipient of several coveted nationally recognized awards, including The ASCO-SITC merit awards, The ASCO merit awards, the ASCO-Young Investigator Award and The NCI Directors Award among several others. Dr. Naqash is an executive member of the SITC Early Career Scientist Committee, the ASCO Trainee and Early Career Council, IASLC Career Development Committee where he is actively involved in working towards developing educational initiatives for early-career investigators. Dr Naqash also serves as the social media editor for JCO Precision Oncology and is a member of the ASCO Social Media Working group developing strategies to facilitate outreach for ASCO journals and ASCO meetings on social media platforms.
Outside of work, Dr. Naqash enjoys traveling, hiking and spending time with his family.

MODERATORS / SPEAKERS

Lauren Price, PharmD
Clinical Pharmacology Team Lead
Division of Cancer Pharmacology II,
US Food & Drug Administration (FDA)

Lauren Price, PharmD, is a Clinical Pharmacology Team Lead in the Division of Cancer Pharmacology II, US Food & Drug Administration (FDA). She obtained a PharmD from the University of Washington School of Pharmacy and subsequently completed an oncology fellowship at the University of North Carolina Eshelman School of Pharmacy. Lauren joined the FDA in 2018 where she reviews and provides regulatory and scientific advice on IND, NDA, and BLA submissions for oncology products. Her current work is primarily focused on products intended to treat breast, gynecologic, and genitourinary cancers.

Biagio Ricciuti, MD, PhD
Physician
Instructor in Medicine, Harvard Medical School

Dr. Biagio Ricciuti is a thoracic medical oncologist and scientist at the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute. His approach to patient care is informed by his clinical and translational research, that focuses on personalized cancer medicine. Dr. Ricciuti's research aims to uncover the mechanisms of response and resistance to immunotherapies and targeted therapies in non-small cell lung cancer, advancing new treatment strategies that can benefit his patients.

He collaborates closely with specialists across oncology disciplines, including radiology, pathology, and surgery, ensuring each patient receives a comprehensive, multidisciplinary approach to care. Dr. Ricciuti is also actively involved in clinical trials and aims to optimize care by tailoring treatment plans to each patient's unique tumor biology and clinical profile.

Summer 2025 NRG Oncology Meeting

Commercial Support

The NRG Oncology Foundation and The GOG Foundation would like to thank and acknowledge the following companies for providing Independent Medical Education (IME) grant support associated with the 2025 NRG/GOG Joint Educational Symposium titled:

Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors

AbbVie

Gilead



GOG FOUNDATION® Transforming the standard of care

NRG ONCOLOGY Advancing Research. Improving Lives.™